Ann: Mesoblast Type A Meeting with FDA, page-276

First 276 Last

Share
Profile

Follow
Theharbinger

1,244 Posts.

118

11/10/23

17:22

Post #: 70293210
Share

Originally posted by stanjupiter: ↑

I could have traded it but I chose not to.

The rants I've been on have been more on the mark than rational posts I've done. I strongly suspected the FDA would knock back Ryoncil in 2020 because I saw damage control in the media and on this forum two years previously. I was hopeful, but far from certain, about this latest BLA.

I wasn't sure the ARDS trial would meet its PE and said so here in a few posts. So many smart-sounding scientists on this forum groomed us to think the trial would be stopped for overwhelming efficacy. They seemed to know Reme was in a salvage position, which I thought was wrong because the cells need peak inflammation. Even if you didn't know that, it doesn't take much reading up about ARDS to learn that regardless of the cause, most patients haven't died by 30 days.

The slow enrolment was also a major red flag. I'd spent time listening to doctors and nurses online. One interview was with a Spanish doctor (around mid 2020) who was asked by a journalist how many Covid patients he had and he said in the hospital system at that time there were six. The journalist got heated and asked him about "the bodies piled in the street" but the doctor said he hadn't seen any. I also knew there was a big push back from clinicians on Remdesivir.

I didn't think the partnership with Novartis would go ahead either. I didn't need the blatant tip offs by the Mexican food item to tell me that. I did say tho I wouldn't be surprised if the deal didn't work out but I got attacked.

I didn't trade the stock because I knew the crisis we were coming into. In order for money to have value you need some kind of functioning society. Societies that embrace the deepest immorality (medical experimentation without informed consent) risk not surviving because they destroy themselves from within.

I do have hope because I suspect a global power shift to the benign. I've said before I suspect a different group demonstrating a high standard of ethics now has control of the pharmaceutical industry. The move to personalised medicine and the increasing use of organoids will be more ethical for patients and could end the testing on animals. It's almost as if an advanced world is hovering just beyond our reach.

Where MSB is concerned, my take is what we're up against has a genuine desire to set the highest bar perhaps because they know the market won't be small. I know MSB isn't perfect but it's the most advanced and my bet is more on the technology. I did hold at one time hoping to make a lot of money but now I hold for insurance reasons. If something actually good isn't allowed to emerge then to me my money doesn't matter because I could never have peace of mind. My fear is not loss of funds but the loss of things that are more precious to me than money.

Expand

your rants are more on the mark then rational ones you say ,

no their not on the money share price is 38 cents brother

the rants are not on the mark u just collect globes
so your a centre link trader basically killing time on internet well done son .

38 cents is not a victory it’s a asx zoombie

MSB Price at posting: 37.5¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

CRI

Critica unveils fresh REE hits near Jupiter play in WA – and 5 new prospects

KNB

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

There are more pages in this discussion • 299 more messages in this thread...

First 276 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.40		Change 0.025(1.82%)		Mkt cap ! $1.592B

Open	High	Low	Value	Volume
$1.40	$1.41	$1.38	$1.394M	997.9K

Buyers (Bids)

No.	Vol.	Price($)
9	24884	$1.40

Sellers (Offers)

Price($)	Vol.	No.
$1.41	47915	12

View Market Depth

No.	Vol.	Price($)
10	44443	1.395
11	125778	1.390
12	124224	1.385
14	280036	1.380
11	83963	1.375

Price($)	Vol.	No.
1.405	10196	5
1.410	103791	16
1.415	77588	10
1.420	95124	8
1.425	129279	9

Last trade - 11.30am 17/10/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Mesoblast Type A Meeting with FDA, page-276

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Critica unveils fresh REE hits near Jupiter play in WA – and 5 new prospects

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Mesoblast Type A Meeting with FDA, page-276

Top Stories

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Critica unveils fresh REE hits near Jupiter play in WA – and 5 new prospects

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News